Drug-resistant tuberculosis treatment success predictors in Namibia.

IF 3.7 Q2 INFECTIOUS DISEASES
JAC-Antimicrobial Resistance Pub Date : 2024-12-18 eCollection Date: 2024-12-01 DOI:10.1093/jacamr/dlae211
Vulika Nangombe, Mondjila Amkongo, Brian Godman, Dan Kibuule
{"title":"Drug-resistant tuberculosis treatment success predictors in Namibia.","authors":"Vulika Nangombe, Mondjila Amkongo, Brian Godman, Dan Kibuule","doi":"10.1093/jacamr/dlae211","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Drug-resistant tuberculosis (DR-TB) is a considerable barrier to ending TB globally by 2035. In most high TB-burden countries in the sub-Saharan region, drivers of DR-TB treatment success are unknown.</p><p><strong>Objectives: </strong>To determine predictors and patterns of treatment success rates (TSRs) in DR-TB in Namibia to inform strategies of national TB programmes.</p><p><strong>Methods: </strong>A nationwide retrospective observational cohort study of a 6 year DR-TB database, 2014-19, was carried out. Independent predictors of successful treatment outcome in DR-TB were determined by multivariate logistic regression.</p><p><strong>Results: </strong>Of the 1494 DR-TB patients included, 56.3% (<i>n</i> = 841) were male, the mean (±SD) age was 35.6 ± 14.2 years, and 8.3% had TB/HIV coinfection. The overall TSR was 66.5% (<i>n</i> = 994) and it increased marginally between implementation of the second and third medium-term plans for TB and leprosy (MTP-II and MTP-III). Being female was associated with lower odds of treatment success [adjusted OR (aOR) = 0.6; 95% CI: 0.34-0.89; <i>P =</i> 0.015), as was a young age (under 5 years) (aOR = 0.1; 95% CI: 0.0007-0.421; <i>P =</i> 0.005) and ages of 5-14 years (aOR = 0.0; 95% CI: 0.002-0.269; <i>P =</i> 0.002). Namibian nationality also showed a reduced likelihood of treatment success (aOR = 0.3; 95% CI: 0.089-0.961; <i>P =</i> 0.043). Among clinical predictors, bilateral pulmonary forms were inversely associated with treatment success (aOR = 0.2; 95% CI: 0.057-0.498; <i>P =</i> 0.001). Conversely, baseline monoresistance was linked to an increased likelihood of treatment success (aOR = 7.6; 95% CI: 1.427-40.631; <i>P =</i> 0.018).</p><p><strong>Conclusions: </strong>Whilst DR-TB TSRs improved, they are below the global target and vary by clinical and patient demographics. Targeted interventions for high-risk patients, including female patients, those aged under 15 years, locals and those with bilateral pulmonary disease using community-based approaches to boost adherence, alongside leveraging the skills of clinical pharmacists, should now be explored.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 6","pages":"dlae211"},"PeriodicalIF":3.7000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086688/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Drug-resistant tuberculosis (DR-TB) is a considerable barrier to ending TB globally by 2035. In most high TB-burden countries in the sub-Saharan region, drivers of DR-TB treatment success are unknown.

Objectives: To determine predictors and patterns of treatment success rates (TSRs) in DR-TB in Namibia to inform strategies of national TB programmes.

Methods: A nationwide retrospective observational cohort study of a 6 year DR-TB database, 2014-19, was carried out. Independent predictors of successful treatment outcome in DR-TB were determined by multivariate logistic regression.

Results: Of the 1494 DR-TB patients included, 56.3% (n = 841) were male, the mean (±SD) age was 35.6 ± 14.2 years, and 8.3% had TB/HIV coinfection. The overall TSR was 66.5% (n = 994) and it increased marginally between implementation of the second and third medium-term plans for TB and leprosy (MTP-II and MTP-III). Being female was associated with lower odds of treatment success [adjusted OR (aOR) = 0.6; 95% CI: 0.34-0.89; P = 0.015), as was a young age (under 5 years) (aOR = 0.1; 95% CI: 0.0007-0.421; P = 0.005) and ages of 5-14 years (aOR = 0.0; 95% CI: 0.002-0.269; P = 0.002). Namibian nationality also showed a reduced likelihood of treatment success (aOR = 0.3; 95% CI: 0.089-0.961; P = 0.043). Among clinical predictors, bilateral pulmonary forms were inversely associated with treatment success (aOR = 0.2; 95% CI: 0.057-0.498; P = 0.001). Conversely, baseline monoresistance was linked to an increased likelihood of treatment success (aOR = 7.6; 95% CI: 1.427-40.631; P = 0.018).

Conclusions: Whilst DR-TB TSRs improved, they are below the global target and vary by clinical and patient demographics. Targeted interventions for high-risk patients, including female patients, those aged under 15 years, locals and those with bilateral pulmonary disease using community-based approaches to boost adherence, alongside leveraging the skills of clinical pharmacists, should now be explored.

纳米比亚耐药结核病治疗成功的预测因素。
背景:耐药结核病(DR-TB)是到2035年全球消除结核病的一个相当大的障碍。在撒哈拉以南地区大多数结核病高负担国家,耐药结核病治疗成功的驱动因素尚不清楚。目的:确定纳米比亚耐药结核病治疗成功率(TSRs)的预测因素和模式,为国家结核病规划的战略提供信息。方法:对2014- 2019年全国6年耐药结核病数据库进行回顾性观察队列研究。通过多变量logistic回归确定耐药结核病成功治疗结果的独立预测因子。结果:纳入的1494例DR-TB患者中,男性占56.3% (n = 841),平均(±SD)年龄为35.6±14.2岁,8.3%合并TB/HIV感染。总体TSR为66.5% (n = 994),在实施第二和第三个结核病和麻风中期计划(MTP-II和MTP-III)期间略有增加。女性患者治疗成功的几率较低[调整OR = 0.6;95% ci: 0.34-0.89;P = 0.015), 5岁以下儿童(aOR = 0.1;95% ci: 0.0007-0.421;P = 0.005), 5 ~ 14岁(aOR = 0.0;95% ci: 0.002-0.269;p = 0.002)。纳米比亚国籍患者治疗成功的可能性也较低(aOR = 0.3;95% ci: 0.089-0.961;p = 0.043)。在临床预测因子中,双侧肺形态与治疗成功呈负相关(aOR = 0.2;95% ci: 0.057-0.498;p = 0.001)。相反,基线单药耐药与治疗成功的可能性增加有关(aOR = 7.6;95% ci: 1.427-40.631;p = 0.018)。结论:虽然耐药结核病tsr有所改善,但仍低于全球目标,并且因临床和患者人口统计数据而异。现在应该探索针对高风险患者(包括女性患者、15岁以下患者、当地人和双侧肺病患者)的针对性干预措施,使用基于社区的方法来提高依从性,同时利用临床药剂师的技能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信